Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT07470983

A Phase II Clinical Study on the Efficacy and Safety of HRS-1780 in Participants With Primary Aldosteronism

A Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of HRS-1780 in Participants With Primary Aldosteronism

Status
Not Yet Recruiting
Phase
Phase 2
Study type
Interventional
Enrollment
60 (estimated)
Sponsor
Shandong Suncadia Medicine Co., Ltd. · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This study is a multicenter, randomized, double-blind, placebo-parallel-controlled phase II clinical trial to evaluate the efficacy and safety of HRS-1780 compared with placebo in participants with primary aldosteronism. The study plans to enroll 60 participants.

Conditions

Interventions

TypeNameDescription
DRUGHRS-1780 TabletsHRS-1780 Tablets
DRUGPlaceboPlacebo

Timeline

Start date
2026-04-01
Primary completion
2026-11-01
Completion
2026-11-01
First posted
2026-03-13
Last updated
2026-04-07

Locations

2 sites across 1 country: China

Source: ClinicalTrials.gov record NCT07470983. Inclusion in this directory is not an endorsement.